Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis

Howes, N.; Neoptolemos, J.P.
December 2002
Gut;Dec2002, Vol. 51 Issue 6, p765
Academic Journal
Comments on research on the risk of pancreatic ductal adenocarcinoma in chronic pancreatitis. Research methodology; Biological evidence supporting the development of chronic pancreatitis to pancreatic ductal adenocarcinoma.


Related Articles

  • Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. Bartsch, Detlef; Shevlin, Douglas W. // JNCI: Journal of the National Cancer Institute;05/15/96, Vol. 88 Issue 10, p680 

    Reports on the decrease in the survival rate of persons afflicted with ductal pancreatic adenocarcinoma. Controversy over surgical resection for the disease; Clinical features associated with prognosis; Mutation of tumor suppressor gene CDKN2; Investigation of tumor DNA for CDKN2 mutations.

  • Clinical Significance of Tumor-associated Antigen RCAS1 Expression in Human Pancreatic Ductal Adenocarcinoma. Demetrios Davides; Apostolos Zarros; Olga Noussia; Adamantia Zizi-Serbetzoglou; Gregorios Kouraklis; Stamatios Theocharis // Digestive Diseases & Sciences;Jun2008, Vol. 53 Issue 6, p1728 

    Abstract  Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a human tumor-associated antigen that induces cell cycle arrest and/or apoptosis in RCAS1 receptor-expressing immune cells. The aim of the present study was to evaluate the clinical significance of RCAS1...

  • Pancreaticoduodenectomy for pancreatic cancer: The Verona experience. MALLEO, GIUSEPPE; MARCHEGIANI, GIOVANNI; SALVIA, ROBERTO; BUTTURINI, GIOVANNI; PEDERZOLI, PAOLO; BASSI, CLAUDIO // Surgery Today;Apr2011, Vol. 41 Issue 4, p463 

    Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related mortality in the Western world. The current treatment is multimodal, and in resectable patients radical surgery represents the key-step toward long-term survival. Pancreaticoduodenectomy (PD) is the most widely...

  • Quantifying the Burden of Complications Following Total Pancreatectomy Using the Postoperative Morbidity Index: A Multi-Institutional Perspective. Datta, Jashodeep; Lewis, Russell; Strasberg, Steven; Hall, Bruce; Allendorf, John; Beane, Joal; Behrman, Stephen; Callery, Mark; Christein, John; Drebin, Jeffrey; Epelboym, Irene; He, Jin; Pitt, Henry; Winslow, Emily; Wolfgang, Christopher; Lee, Major; Vollmer, Charles // Journal of Gastrointestinal Surgery;Mar2015, Vol. 19 Issue 3, p506 

    Background: While contemporary studies demonstrate decreasing complication rates following total pancreatectomy (TP), none have quantified the impact of post-TP complications. The Postoperative Morbidity Index (PMI)-a quantitative measure of postoperative morbidity-combines ACS-NSQIP...

  • Tumorigenesis: Disconnecting Hedgehog from GLI. Seton-Rogers, Sarah // Nature Reviews Cancer;Mar2009, Vol. 9 Issue 3, p150 

    The article reports on the result of a study conducted by Doug Hanahan and colleagues concerning the possible role of hedgehog signalling pathway in pancreatic ductal adenocarcinoma formation. They used genetic deletion of smoothened SMO, the co-receptor for the sonic hedgehog ligand SSH,...

  • Stromal biology and therapy in pancreatic cancer. Albrecht Neesse // Gut;Jun2011, Vol. 60 Issue 6, p861 

    Pancreatic ductal adenocarcinoma (PDA) is an almost uniformly lethal disease. One explanation for the devastating prognosis is the failure of many chemotherapies, including the current standard of care therapy gemcitabine. Although our knowledge of the molecular events underlying multistep...

  • High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas. Yanagisawa, Nobuyuki; Ichinoe, Masaaki; Mikami, Tetuo; Nakada, Norihiro; Hana, Kiyomi; Koizumi, Wasaburo; Endou, Hitoshi; Okayasu, Isao // Journal of Clinical Pathology;Nov2012, Vol. 65 Issue 11, p1019 

    Background and aims Molecular target therapy against L-type amino acid transporter 1 (LAT1) is unique and expected to be developed soon. LAT1 expression was investigated in pancreatic cancer as a prognostic predictor. Methods Surgically resected pancreatic ductal adenocarcinomas (PDAC, n=66)...

  • BAG3 Is a Novel Serum Biomarker for Pancreatic Adenocarcinomas. Falco, Antonia; Rosati, Alessandra; Festa, Michelina; Basile, Anna; De Marco, Margot; d'Avenia, Morena; Pascale, Maria; Dal Piaz, Fabrizio; Tavano, Francesca; Di Mola, Fabio Francesco; di Sebastiano, Pierluigi; Berloco, Pasquale Bartolomeo; Nudo, Francesco; Caraglia, Michele; Febbraro, Antonio; Barcaroli, Daniela; Scarpa, Aldo; Pezzilli, Raffaele; De Laurenzi, Vincenzo; Turco, Maria Caterina // American Journal of Gastroenterology;Jul2013, Vol. 108 Issue 7, p1178 

    The article focuses on pancreatic ductal adenocarcinoma (PDAC), which is one of the five most lethal malignancies and states that it was found that the intracellular anti-apoptotic protein BAG3 used to get expressed in PDAC tumor patients, according to a report. It further investigated whether...

  • Apoptotic pathways in pancreatic ductal adenocarcinoma. Hamacher, Rainer; Schmid, Roland M.; Saur, Dieter; Schneider, Günter // Molecular Cancer;2008, Vol. 7, Special section p1 

    Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer related death. Despite the advances in understanding of the molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. Overall, the 5-year survival rate is less than 5% demonstrating the...


Read the Article


Sign out of this library

Other Topics